JPRN-UMIN000042750
尚未招募
未知
Efficacy of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma - Efficacy of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Gifu university first Dept of internalmedicine0 个研究点目标入组 300 人2020年12月21日
概览
- 阶段
- 未知
- 干预措施
- 未指定
- 疾病 / 适应症
- Hepatocellular Carcinoma
- 发起方
- Gifu university first Dept of internalmedicine
- 入组人数
- 300
- 状态
- 尚未招募
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- 未提供
排除标准
- •1Untreated or incompletely treated esophageal or gastric varices.2With bleeding or high risk of bleeding.3Thromboembolic event.4Wounded.5Brain metastasis.6Uncontrolled Hypertension. 7Uncontrolled Ascites. 8History of autoimmune disease. 9Pulmonary fibrosis. 10Tuberculosis. 11Severe Hart failure. 12Long QT Syndrome. 13infection within 4weeks. 14Vaccination within 4weeks. 15Pregnant. 16Allergic. 17Un suitable Patient.
结局指标
主要结局
未指定
相似试验
已完成
2 期
A Phase II Study of Atezolizumab with Bevacizumab for Patients with Non-Small Cell Non-Squamous Cell Lung Cancer (At Be Study) (Investigator-Initiated Clinical Trial)non-small-cell lung cancerJPRN-jRCT2080223980Takashi Seto (Coordinating Investigator)38
已完成
不适用
Biomarker study of Atezolizumab plus Bevacizumab for PD-L1 High Non-Sq NSCLCnon-small-cell lung cancerJPRN-jRCT1080224072Kaname Nosaki (Principal Investigator)38
进行中（未招募）
2 期
Atezo+Bev study for pretreated patientshepatocellular carcinomaJPRN-jRCT1041200068Yamashita Tatsuya28
进行中（未招募）
1 期
Evaluation of treatment combination Atezolizumab/Bevacizumab +/- Chemotherapy in patients with recurrent ovarian cancerEfficacy of atezolizumab in combination with non-platinum based chemotherapy and bevacizumab versus the combination of a non-platinum based chemotherapy and bevacizumab in recurrent ovarian cancerMedDRA version: 27.0Level: PTClassification code 10016182Term: Fallopian tube cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 27.0Level: PTClassification code 10057529Term: Ovarian cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-000202-37-LTAGO Research GmbH550
进行中（未招募）
1 期
Evaluation of treatment combination Atezolizumab/Bevacizumab +/- Chemotherapy in patients with recurrent ovarian cancerEUCTR2017-000202-37-NOAGO Research GmbH664